Jazz Pharmaceuticals (NASDAQ:JAZZ) Announces Earnings Results

Jazz Pharmaceuticals (NASDAQ:JAZZ) announced its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.05) by $0.17, FiscalAI reports. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%.

Here are the key takeaways from Jazz Pharmaceuticals’ conference call:

• Positive Sentiment: Jazz reported record third-quarter revenue of $1.24 billion, up 10% year over year, and raised 2026 revenue guidance to $4.775 billion–$4.85 billion. The company cited broad commercial execution across sleep, oncology and international markets while keeping operating-expense guidance unchanged.
• Positive Sentiment: Ziihera’s launch in first-line HER2-positive metastatic gastroesophageal adenocarcinoma generated $21 million in third-quarter sales and showed strong early community adoption, including a threefold increase in new ordering accounts in September. Jazz estimates a 3,000–4,000-patient annual U.S. addressable population and increased Ziihera’s peak-sales potential to $3 billion–$5 billion.
• Positive Sentiment: Xywav sales rose 12% to $483 million, with approximately 425 net patient additions during the quarter. Management said high-sodium oxybate generics have had limited impact so far and expects Xywav’s low-sodium profile and clinical differentiation to support continued durability into 2027.
• Positive Sentiment: Jazz completed its $820 million acquisition of Actio Biosciences, adding ABS-1230, a precision epilepsy therapy targeting KCNT1 mutations. Initial patient efficacy data are expected this quarter, while the company also advanced its orexin-2 agonist JZP269 into a Phase I trial.
• Negative Sentiment: Zepzelca faces a likely competitive headwind in 2027 from Amgen’s IMDELLTRA following strong first-line maintenance small-cell lung cancer data, although management expects no impact to 2026 guidance. Modeyso revenue growth may also proceed at a more measured pace as Jazz expands from academic centers into community oncology ahead of the ACTION trial readout in the first half of 2027.

Jazz Pharmaceuticals Trading Down 0.7%

Shares of NASDAQ:JAZZ traded down $1.54 during trading on Monday, reaching $214.44. The company’s stock had a trading volume of 1,042,884 shares, compared to its average volume of 931,315. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals has a 12 month low of $128.80 and a 12 month high of $266.38. The firm’s 50 day simple moving average is $231.96 and its two-hundred day simple moving average is $216.24. The stock has a market capitalization of $13.92 billion, a PE ratio of 14.79, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on JAZZ shares. Weiss Ratings lowered Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday. Barclays increased their price target on Jazz Pharmaceuticals from $270.00 to $271.00 and gave the company an “overweight” rating in a research note on Thursday, September 10th. The Goldman Sachs Group started coverage on Jazz Pharmaceuticals in a report on Thursday, September 24th. They set a “buy” rating and a $337.00 price target for the company. Wells Fargo & Company raised their price target on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, Stifel Nicolaus set a $275.00 price objective on Jazz Pharmaceuticals in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.05.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena Patil sold 1,200 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total transaction of $289,128.00. Following the sale, the executive vice president directly owned 47,671 shares of the company’s stock, valued at $11,485,850.74. The trade was a 2.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the sale, the executive vice president owned 65,686 shares in the company, valued at approximately $16,401,794.20. This trade represents a 53.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 94,121 shares of company stock valued at $23,337,922. Insiders own 4.10% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.